Adagene Inc Cash Flow Conversion Efficiency
Adagene Inc cash flow conversion efficiency. Based on the latest financial reports, Adagene Inc (ADAG) has a cash flow conversion efficiency ratio of -0.139x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.75 Million) by net assets ($106.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Adagene Inc (2018–2025)
Cash flow conversion efficiency of Adagene Inc from 2018 to 2025. This chart illustrates how Adagene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Adagene Inc stock price today for real-time trading data and today's change.
Adagene Inc Cash Flow Conversion Ratio Explained
Adagene Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Adagene Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adagene Inc ranked by their cash flow conversion efficiency. Also see ADAG company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UNISEM Co. Ltd
KQ:036200
|
0.022x |
|
Dividend 15 Split Corp II
TO:DF
|
-0.012x |
|
TS Corporation
KO:001790
|
0.052x |
|
Yayla Agro Gida Sanayi ve Ticaret A.S.
IS:YYLGD
|
0.339x |
|
Sunjin
KO:136490
|
0.001x |
|
Stoneridge Inc
NYSE:SRI
|
0.056x |
|
Wah Hong Industrial
TWO:8240
|
0.026x |
|
Answer Technology Co Ltd
TW:3528
|
-1.025x |
Annual Cash Flow Conversion Efficiency for Adagene Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Adagene Inc from 2018 to 2025. Review Adagene Inc (ADAG) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $35.35 Million | $-15.66 Million | -0.443x | +24.65% |
| 2024-12-31 | $50.52 Million | $-29.70 Million | -0.588x | -45.77% |
| 2023-12-31 | $70.56 Million | $-28.45 Million | -0.403x | +31.07% |
| 2022-12-31 | $83.09 Million | $-48.61 Million | -0.585x | -110.98% |
| 2021-12-31 | $156.56 Million | $-43.41 Million | -0.277x | -186.89% |
| 2020-12-31 | $-89.39 Million | $-28.53 Million | 0.319x | +0.23% |
| 2019-12-31 | $-57.01 Million | $-18.15 Million | 0.318x | -8.42% |
| 2018-12-31 | $-41.03 Million | $-14.26 Million | 0.348x | -- |
About Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more